Please enable JavaScript to continue using this application.

Compare $CELU vs $KLRS | Chartloom

Compare

$CELU vs $KLRS

Celularity Inc · Kalaris Therapeutics Inc

CELU

Celularity Inc

KLRS

Kalaris Therapeutics Inc

Compare $CELU vs $KLRS

Comparing Celularity Inc and Kalaris Therapeutics Inc

CELUCelularity Inc

KLRSKalaris Therapeutics Inc

CELUCelularity Inc

Market cap

$45M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-51.0%

YTD performance

28.9%

52W performance

-27.4%

FCF yield

-29.3%

KLRSKalaris Therapeutics Inc

Market cap

$56M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-71.6%

52W performance

-64.2%

FCF yield

-73.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CELU

KLRS

Detailed metrics comparison

CELU

Celularity Inc

KLRS

Kalaris Therapeutics Inc

Market Cap

CELU$45M

KLRS$56M

Enterprise Value

CELU$87M

KLRS$45M

Price

CELU$1.56

KLRS$2.36

P/E Ratio

CELUN/A

KLRSN/A

P/S Ratio

CELU1.70x

KLRS0.00x

EV/Sales

CELU3.27x

KLRS0.00x

EV/EBITDA

CELU0.00x

KLRS0.00x

P/B Ratio

CELU5.88x

KLRS1.02x

P/FCF Ratio

CELUN/A

KLRSN/A

EV/FCF

CELU-6.55x

KLRS-1.09x

PEG Ratio

CELUN/A

KLRSN/A

Forward P/E (NTM)

CELUN/A

KLRSN/A

Forward P/S (NTM)

CELUN/A

KLRSN/A

Revenue (TTM)

CELU$27M

KLRS$0

Revenue Growth (YoY)

CELU-51.0%

KLRSN/A

Forward Rev Growth

CELU0.0%

KLRS180.3%

Gross Margin (TTM)

CELU24.4%

KLRS0.0%

Operating Margin (TTM)

CELU0.0%

KLRS0.0%

EBITDA Margin (TTM)

CELU-203.4%

KLRS0.0%

Net Margin (TTM)

CELU-346.0%

KLRS0.0%

FCF Margin (TTM)

CELU-49.9%

KLRSN/A

Net Income (TTM)

CELU$-92M

KLRS$-44M

FCF (TTM)

CELU$-13M

KLRS$-41M

EPS (TTM)

CELU-$3.23

KLRS-$1.86

ROE (TTM)

CELU-27244.0%

KLRS-7171.0%

ROA (TTM)

CELU-7794.0%

KLRS-4295.0%

ROIC (TTM)

CELU-9204.0%

KLRS-4719.0%

Cash

CELU$6M

KLRS$43M

Debt

CELU$48M

KLRS$32M

Net Cash/Debt

CELU$-42M

KLRS$11M

Current Ratio (TTM)

CELU0.15x

KLRS10.98x

Quick Ratio (TTM)

CELU0.14x

KLRS10.76x

Debt/Equity (TTM)

CELU4.79x

KLRS0.56x

Debt/Assets (TTM)

CELU0.0%

KLRS0.0%

Interest Coverage (TTM)

CELUN/A

KLRSN/A

Net Debt/EBITDA (TTM)

CELU0.00x

KLRS0.00x

Beta

CELU0.88

KLRS0.44

52W Performance

CELU-27.4%

KLRS-64.2%

YTD Performance

CELU28.9%

KLRS-71.6%

% from 52W High

CELU-38.8%

KLRS-80.1%

% from 52W Low

CELU178.5%

KLRS0.4%

Asset Turnover (TTM)

CELU0.23x

KLRS0.00x

FCF Yield (TTM)

CELU-29.3%

KLRS-73.4%

Earnings Yield (TTM)

CELU-203.4%

KLRS-78.8%

Dividend Yield (TTM)

CELUN/A

KLRSN/A

Rule of 40

CELU-101.0

KLRS0.0

EV/GP/RG

CELUN/A

KLRSN/A

Ticker research

View CELU research View KLRS research

Metric	CELU Celularity Inc	KLRS Kalaris Therapeutics Inc
Market & Valuation
Market Cap	$45M	$56M
Enterprise Value	$87M	$45M
Price	$1.56	$2.36
P/E Ratio	N/A	N/A
P/S Ratio	1.70x	0.00x
EV/Sales	3.27x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	5.88x	1.02x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.55x	-1.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$27M	$0
Revenue Growth (YoY)	-51.0%	N/A
Forward Rev Growth	0.0%	180.3%
Profitability
Gross Margin (TTM)	24.4%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-203.4%	0.0%
Net Margin (TTM)	-346.0%	0.0%
FCF Margin (TTM)	-49.9%	N/A
Net Income (TTM)	$-92M	$-44M
FCF (TTM)	$-13M	$-41M
EPS (TTM)	-$3.23	-$1.86
ROE (TTM)	-27244.0%	-7171.0%
ROA (TTM)	-7794.0%	-4295.0%
ROIC (TTM)	-9204.0%	-4719.0%
Financial Health
Cash	$6M	$43M
Debt	$48M	$32M
Net Cash/Debt	$-42M	$11M
Current Ratio (TTM)	0.15x	10.98x
Quick Ratio (TTM)	0.14x	10.76x
Debt/Equity (TTM)	4.79x	0.56x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.88	0.44
52W Performance	-27.4%	-64.2%
YTD Performance	28.9%	-71.6%
% from 52W High	-38.8%	-80.1%
% from 52W Low	178.5%	0.4%
Efficiency & Yields
Asset Turnover (TTM)	0.23x	0.00x
FCF Yield (TTM)	-29.3%	-73.4%
Earnings Yield (TTM)	-203.4%	-78.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-101.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CELU research	View KLRS research

Valuation

P/S Ratio

KLRS

0.00x

CELU

1.70x

EV/FCF

CELU

-6.55x

KLRS

-1.09x

Growth & revenue

Revenue Growth TTM

CELU

-51.0%

Forward Revenue Growth

KLRS

180.3%

CELU

0.0%

Profitability & performance

Gross Margin

CELU

24.4%

KLRS

0.0%

ROE

KLRS

-7171.0%

CELU

-27244.0%

FCF Yield %

CELU

-29.3%

KLRS

-73.4%

52-Week Performance

CELU

-27.4%

KLRS

-64.2%

Detailed metrics comparison

CELU

Celularity Inc

KLRS

Kalaris Therapeutics Inc

Market Cap

CELU$45M

KLRS$56M

Enterprise Value

CELU$87M

KLRS$45M

Price

CELU$1.56

KLRS$2.36

P/E Ratio

CELUN/A

KLRSN/A

P/S Ratio

CELU1.70x

KLRS0.00x

EV/Sales

CELU3.27x

KLRS0.00x

EV/EBITDA

CELU0.00x

KLRS0.00x

P/B Ratio

CELU5.88x

KLRS1.02x

P/FCF Ratio

CELUN/A

KLRSN/A

EV/FCF

CELU-6.55x

KLRS-1.09x

PEG Ratio

CELUN/A

KLRSN/A

Forward P/E (NTM)

CELUN/A

KLRSN/A

Forward P/S (NTM)

CELUN/A

KLRSN/A

Revenue (TTM)

CELU$27M

KLRS$0

Revenue Growth (YoY)

CELU-51.0%

KLRSN/A

Forward Rev Growth

CELU0.0%

KLRS180.3%

Gross Margin (TTM)

CELU24.4%

KLRS0.0%

Operating Margin (TTM)

CELU0.0%

KLRS0.0%

EBITDA Margin (TTM)

CELU-203.4%

KLRS0.0%

Net Margin (TTM)

CELU-346.0%

KLRS0.0%

FCF Margin (TTM)

CELU-49.9%

KLRSN/A

Net Income (TTM)

CELU$-92M

KLRS$-44M

FCF (TTM)

CELU$-13M

KLRS$-41M

EPS (TTM)

CELU-$3.23

KLRS-$1.86

ROE (TTM)

CELU-27244.0%

KLRS-7171.0%

ROA (TTM)

CELU-7794.0%

KLRS-4295.0%

ROIC (TTM)

CELU-9204.0%

KLRS-4719.0%

Cash

CELU$6M

KLRS$43M

Debt

CELU$48M

KLRS$32M

Net Cash/Debt

CELU$-42M

KLRS$11M

Current Ratio (TTM)

CELU0.15x

KLRS10.98x

Quick Ratio (TTM)

CELU0.14x

KLRS10.76x

Debt/Equity (TTM)

CELU4.79x

KLRS0.56x

Debt/Assets (TTM)

CELU0.0%

KLRS0.0%

Interest Coverage (TTM)

CELUN/A

KLRSN/A

Net Debt/EBITDA (TTM)

CELU0.00x

KLRS0.00x

Beta

CELU0.88

KLRS0.44

52W Performance

CELU-27.4%

KLRS-64.2%

YTD Performance

CELU28.9%

KLRS-71.6%

% from 52W High

CELU-38.8%

KLRS-80.1%

% from 52W Low

CELU178.5%

KLRS0.4%

Asset Turnover (TTM)

CELU0.23x

KLRS0.00x

FCF Yield (TTM)

CELU-29.3%

KLRS-73.4%

Earnings Yield (TTM)

CELU-203.4%

KLRS-78.8%

Dividend Yield (TTM)

CELUN/A

KLRSN/A

Rule of 40

CELU-101.0

KLRS0.0

EV/GP/RG

CELUN/A

KLRSN/A

Ticker research

View CELU research View KLRS research

Metric	CELU Celularity Inc	KLRS Kalaris Therapeutics Inc
Market & Valuation
Market Cap	$45M	$56M
Enterprise Value	$87M	$45M
Price	$1.56	$2.36
P/E Ratio	N/A	N/A
P/S Ratio	1.70x	0.00x
EV/Sales	3.27x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	5.88x	1.02x
P/FCF Ratio	N/A	N/A
EV/FCF	-6.55x	-1.09x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$27M	$0
Revenue Growth (YoY)	-51.0%	N/A
Forward Rev Growth	0.0%	180.3%
Profitability
Gross Margin (TTM)	24.4%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-203.4%	0.0%
Net Margin (TTM)	-346.0%	0.0%
FCF Margin (TTM)	-49.9%	N/A
Net Income (TTM)	$-92M	$-44M
FCF (TTM)	$-13M	$-41M
EPS (TTM)	-$3.23	-$1.86
ROE (TTM)	-27244.0%	-7171.0%
ROA (TTM)	-7794.0%	-4295.0%
ROIC (TTM)	-9204.0%	-4719.0%
Financial Health
Cash	$6M	$43M
Debt	$48M	$32M
Net Cash/Debt	$-42M	$11M
Current Ratio (TTM)	0.15x	10.98x
Quick Ratio (TTM)	0.14x	10.76x
Debt/Equity (TTM)	4.79x	0.56x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.88	0.44
52W Performance	-27.4%	-64.2%
YTD Performance	28.9%	-71.6%
% from 52W High	-38.8%	-80.1%
% from 52W Low	178.5%	0.4%
Efficiency & Yields
Asset Turnover (TTM)	0.23x	0.00x
FCF Yield (TTM)	-29.3%	-73.4%
Earnings Yield (TTM)	-203.4%	-78.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-101.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CELU research	View KLRS research